Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and global expansion of sales of its diabetes and weight loss drugs should all add up to strong, 32% sales growth in the new year. The company forecasts 2025 sales of $58 billion to $61 billion.

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more weightbut not enough to dethrone Eli Lilly's Zepbound

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale shift of injectable drugs that treat obesity,

Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The number ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.